{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:15:29Z","timestamp":1793945729343,"version":"4.8.0"},"reference-count":42,"publisher":"BMJ","issue":"7","funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-14-CE15-0001-MECANO"],"award-info":[{"award-number":["ANR-14-CE15-0001-MECANO"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-18-RHUS-0012"],"award-info":[{"award-number":["ANR-18-RHUS-0012"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002915","name":"Fondation pour la Recherche M\u00e9dicale","doi-asserted-by":"publisher","award":["DQ20170336751"],"award-info":[{"award-number":["DQ20170336751"]}],"id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"accepted":{"date-parts":[[2020,4,8]]},"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To describe the spectrum and outcome of central nervous system complications associated with immune checkpoint inhibitors (CNS-ICI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with CNS-ICI were identified and their characteristics compared with ICI-related peripheral neuropathy (PN-ICI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 19 patients with CNS-ICI. The patients were receiving nivolumab (n=8), pembrolizumab (n=6), a combination of ipilimumab-nivolumab (n=3), ipilimumab-durvalumab (n=1), or atezolizumab (n=1). Underlying malignancies included non-small-cell lung cancer (n=8), melanoma (n=3), and other less common tumours (n=8). Neurological phenotypes were limbic encephalitis (n=8), meningoencephalitis (n=4) and cerebellitis (n=4). Two patients developed isolated confusion and one parkinsonism. Associated autoantibodies included onconeural (Ma2, n=7; Hu, n=1), astrocytic (glial fibrillar acidic protein, n=2) and neuronal surface (contactin-associated protein-like 2, n=1) specificities. ICIs were withheld and corticosteroid treatment was given in all cases. Five patients received intravenous immunoglobulin, two rituximab, one plasmapheresis and one infliximab. Overall, six patients died. Readministration of ICI was attempted in three patients, without further relapses. Non-small-cell lung cancer was significantly more frequent in patients with CNS-ICI (p&lt;0.01), while melanoma and ipilimumab treatment were more common in PN-ICI (p&lt;0.01\u2009and p=0.01). Conversely, CNS-ICI cases were more frequently antibody-positive than PN-ICI (p&lt;0.01) and showed a strong trend towards poorer outcome (p=0.053).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Three main clinical phenotypes characterise CNS complications of ICIs, each with distinct immunological background, disease course and response to treatment. Other clinical manifestations (including parkinsonism and steroid-responsive confusion) are also possible. Underlying cancers, antibody prevalence and outcome appear different from those of patients with PN-ICI.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jnnp-2020-323055","type":"journal-article","created":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T17:15:46Z","timestamp":1587402946000},"page":"772-778","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":143,"title":["Central nervous system complications associated with immune checkpoint inhibitors"],"prefix":"10.1136","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3652-7061","authenticated-orcid":false,"given":"Alberto","family":"Vogrig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5958-3288","authenticated-orcid":false,"given":"Sergio","family":"Mu\u00f1iz-Castrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastien","family":"Joubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraldine","family":"Picard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Rogemond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Marchal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Marie","family":"Chiappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eve","family":"Chanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Skowron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelie","family":"Leblanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Ducray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Honnorat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,4,20]]},"reference":[{"key":"2024111108300562000_91.7.772.1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060"},{"key":"2024111108300562000_91.7.772.2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aww225"},{"key":"2024111108300562000_91.7.772.3","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000604"},{"key":"2024111108300562000_91.7.772.4","doi-asserted-by":"crossref","first-page":"e1093","DOI":"10.1212\/WNL.0000000000008091","article-title":"Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies","volume":"93","author":"Dubey","year":"2019","journal-title":"Neurology"},{"key":"2024111108300562000_91.7.772.5","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1212\/WNL.0000000000004359","article-title":"Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan","volume":"89","author":"Suzuki","year":"2017","journal-title":"Neurology"},{"key":"2024111108300562000_91.7.772.6","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006124"},{"key":"2024111108300562000_91.7.772.7","doi-asserted-by":"crossref","DOI":"10.1007\/s11910-018-0810-1","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: diagnosis and management","volume":"18","author":"Astaras","year":"2018","journal-title":"Curr Neurol Neurosci Rep"},{"key":"2024111108300562000_91.7.772.8","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2017.1912","article-title":"Neurological complications associated with Anti-Programmed death 1 (PD-1) antibodies","volume":"74","author":"Kao","year":"2017","journal-title":"JAMA Neurol"},{"key":"2024111108300562000_91.7.772.9","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/annonc\/mdw558","article-title":"Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature","volume":"28","author":"Spain","year":"2017","journal-title":"Ann Oncol"},{"key":"2024111108300562000_91.7.772.10","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv623"},{"key":"2024111108300562000_91.7.772.11","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jns.2015.01.028","article-title":"Anti-Ma-associated encephalomyeloradiculopathy in a patient with pleural mesothelioma","volume":"350","author":"Vogrig","year":"2015","journal-title":"J Neurol Sci"},{"key":"2024111108300562000_91.7.772.12","doi-asserted-by":"crossref","DOI":"10.1186\/s13256-018-1786-9","article-title":"Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report","volume":"12","author":"Kopeck\u00fd","year":"2018","journal-title":"J Med Case Rep"},{"key":"2024111108300562000_91.7.772.13","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1093\/jjco\/hyz087","article-title":"Nivolumab-induced autoimmune encephalitis in an anti-neuronal autoantibody-positive patient","volume":"49","author":"Shibaki","year":"2019","journal-title":"Jpn J Clin Oncol"},{"key":"2024111108300562000_91.7.772.14","unstructured":"Leempoel J , Ruyssen A , Kessler R , et al . Anti-Ma2\/Ta paraneoplastic rhombencephalitis in a patient with lung cancer responsive to anti-PD1 therapy. Acta Neurol Belg."},{"key":"2024111108300562000_91.7.772.15","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000701","article-title":"Diagnostic yield of commercial immunodots to diagnose paraneoplastic neurologic syndromes","volume":"7","author":"D\u00e9chelotte","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2024111108300562000_91.7.772.16","doi-asserted-by":"crossref","first-page":"e597","DOI":"10.1016\/j.cllc.2018.04.009","article-title":"Nivolumab-induced limbic encephalitis with anti-Hu antibody in a patient with advanced pleomorphic carcinoma of the lung","volume":"19","author":"Matsuoka","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"2024111108300562000_91.7.772.17","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0344"},{"key":"2024111108300562000_91.7.772.18","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.lungcan.2017.05.002","article-title":"Recurrent dysphasia due to nivolumab-induced encephalopathy with presence of Hu autoantibody","volume":"109","author":"Raskin","year":"2017","journal-title":"Lung Cancer"},{"key":"2024111108300562000_91.7.772.19","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000439","article-title":"Natalizumab may control immune checkpoint inhibitor\u2013induced limbic encephalitis","volume":"5","author":"Hottinger","year":"2018","journal-title":"Neurology - Neuroimmunology Neuroinflammation"},{"key":"2024111108300562000_91.7.772.20","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.gore.2018.03.007","article-title":"A case of severe encephalitis while on PD-1 immunotherapy for recurrent clear cell ovarian cancer","volume":"24","author":"Burke","year":"2018","journal-title":"Gynecol Oncol Rep"},{"key":"2024111108300562000_91.7.772.21","article-title":"Nivolumab-Induced autoimmune encephalitis in two patients with lung adenocarcinoma","volume":"2018","author":"Shah","year":"2018","journal-title":"Case Rep Neurol Med"},{"key":"2024111108300562000_91.7.772.22","unstructured":"Chung M , Jaffer M , Verma N , et al . Immune checkpoint inhibitor induced anti-glutamic acid decarboxylase 65 (anti-GAD 65) limbic encephalitis responsive to intravenous immunoglobulin and plasma exchange. J Neurol."},{"key":"2024111108300562000_91.7.772.23","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000007971","article-title":"Phosphodiesterase 10A IgG: a novel biomarker of paraneoplastic neurologic autoimmunity","volume":"93","author":"Zekeridou","year":"2019","journal-title":"Neurology"},{"key":"2024111108300562000_91.7.772.24","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2016.1399","article-title":"Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer","volume":"73","author":"Williams","year":"2016","journal-title":"JAMA Neurol"},{"key":"2024111108300562000_91.7.772.25","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0727-5"},{"key":"2024111108300562000_91.7.772.26","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jneuroim.2016.12.016","article-title":"Autoimmune limbic encephalitis with anti-contactin-associated protein-like 2 antibody secondary to pembrolizumab therapy","volume":"305","author":"Brown","year":"2017","journal-title":"J Neuroimmunol"},{"key":"2024111108300562000_91.7.772.27","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/WCO.0000000000000676","article-title":"Autoimmune glial fibrillary acidic protein astrocytopathy","volume":"32","author":"Kunchok","year":"2019","journal-title":"Curr Opin Neurol"},{"key":"2024111108300562000_91.7.772.28","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00819","article-title":"Dramatic response of leptomeningeal carcinomatosis to nivolumab in PD-L1 highly expressive non-small cell lung cancer: a case report","volume":"9","author":"Arias Ron","year":"2019","journal-title":"Front Oncol"},{"key":"2024111108300562000_91.7.772.29","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.mayocpiqo.2017.12.001","article-title":"Association of immune-mediated cerebellitis with immune checkpoint inhibitor therapy","volume":"2","author":"Zurko","year":"2018","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"2024111108300562000_91.7.772.30","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1007\/s10072-018-3465-4","article-title":"Acute cerebellitis after administration of nivolumab and ipilimumab for small cell lung cancer","volume":"39","author":"Naito","year":"2018","journal-title":"Neurol Sci"},{"key":"2024111108300562000_91.7.772.31","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s10072-017-3222-0","article-title":"Expanding spectrum of contactin-associated protein 2 (CASPR2) autoimmunity-syndrome of parkinsonism and ataxia","volume":"39","author":"Kannoth","year":"2018","journal-title":"Neurol Sci"},{"key":"2024111108300562000_91.7.772.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.02.024"},{"key":"2024111108300562000_91.7.772.33","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/acn3.547","article-title":"Seronegative antibody-mediated neurology after immune checkpoint inhibitors","volume":"5","author":"Wilson","year":"2018","journal-title":"Ann Clin Transl Neurol"},{"key":"2024111108300562000_91.7.772.34","unstructured":"Vogrig A , Joubert B , Maureille A , et al . Motor neuron involvement in anti-Ma2-associated paraneoplastic neurological syndrome. J Neurol."},{"key":"2024111108300562000_91.7.772.35","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awh203"},{"key":"2024111108300562000_91.7.772.36","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s00415-019-09544-1","article-title":"Epidemiology of paraneoplastic neurological syndromes: a population-based study","volume":"267","author":"Vogrig","year":"2020","journal-title":"J Neurol"},{"key":"2024111108300562000_91.7.772.37","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0523-2"},{"key":"2024111108300562000_91.7.772.38","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0805-8"},{"key":"2024111108300562000_91.7.772.39","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1395125","article-title":"Assessment of neuronal autoantibodies in patients with small cell lung cancer treated with chemotherapy with or without ipilimumab","volume":"7","author":"Hardy-Werbin","year":"2018","journal-title":"Oncoimmunology"},{"key":"2024111108300562000_91.7.772.40","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1212\/WNL.0000000000007235","article-title":"Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: systematic review","volume":"92","author":"Johansen","year":"2019","journal-title":"Neurology"},{"key":"2024111108300562000_91.7.772.41","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00530","article-title":"Immune-related adverse events: a case-based approach","volume":"9","author":"Connolly","year":"2019","journal-title":"Front Oncol"},{"key":"2024111108300562000_91.7.772.42","doi-asserted-by":"publisher","DOI":"10.1177\/0020715206070267"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2020-323055","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T11:32:03Z","timestamp":1731324723000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2020-323055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,20]]},"references-count":42,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,6,18]]},"published-print":{"date-parts":[[2020,7]]}},"alternative-id":["10.1136\/jnnp-2020-323055"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2020-323055","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,20]]}}}